Loading…
Recombinant Vaccinia/Fowlpox NY-ESO-1 Vaccines Induce Both Humoral and Cellular NY-ESO-1-Specific Immune Responses in Cancer Patients
NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series o...
Saved in:
| Published in: | Proceedings of the National Academy of Sciences - PNAS 2006-09, Vol.103 (39), p.14453-14458 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5113-9f739873e2daccc2f8ee9361d3d73940d177c95f07263de15f4b4bf0087168f43 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5113-9f739873e2daccc2f8ee9361d3d73940d177c95f07263de15f4b4bf0087168f43 |
| container_end_page | 14458 |
| container_issue | 39 |
| container_start_page | 14453 |
| container_title | Proceedings of the National Academy of Sciences - PNAS |
| container_volume | 103 |
| creator | Jäger, Elke Karbach, Julia Gnjatic, Sacha Neumann, Antje Bender, Armin Valmori, Danila Ayyoub, Maha Ritter, Erika Ritter, Gerd Jäger, Dirk Panicali, Dennis Hoffman, Eric Pan, Linda Oettgen, Herbert Old, Lloyd J. Knuth, Alexander |
| description | NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination. |
| doi_str_mv | 10.1073/pnas.0606512103 |
| format | article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_19360711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30050395</jstor_id><sourcerecordid>30050395</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5113-9f739873e2daccc2f8ee9361d3d73940d177c95f07263de15f4b4bf0087168f43</originalsourceid><addsrcrecordid>eNqFkk9v1DAQxS0EotuFMyeQxQGJQ7ozsfPHFyRYtXSliqIWkDhZXsehXiV2iJNSPgDfGy8b7QKXnnyY3zy_NzOEPEM4QSjYonMqnEAOeYYpAntAZggCk5wLeEhmAGmRlDzlR-Q4hA0AiKyEx-QIc1FyIcoZ-XVltG_X1ik30C9Ka-usWpz5H03n7-iHr8np9WWCU8UEunLVqA1954cbej62vlcNVa6iS9M0Y6P6fUty3Rlta6vpqm1HZ-iVCZ13IWpYR5fKadPTj2qwxg3hCXlUqyaYp9M7J5_PTj8tz5OLy_er5duLRGeILBF1wURZMJNW0Y9O69IYwXKsWBULHCosCi2yGoo0Z5XBrOZrvq4BygLzsuZsTt7sdLtx3ZpKx79jANn1tlX9T-mVlf9WnL2R3_ytxKwALNMo8GoS6P330YRBtjbomF0548cg81IA8riJ-0CMvqGIoebk5X_gxo-9i1OQKSD7s7MILXaQ7n0Ivan3lhHk9hDk9hDk4RBix4u_kx74afMReD0B286DHJNMSOQ8Y7Iem2Ywd0Nk6T1sRJ7vkE0YfL9nov8MWEzwGzcY0EU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201300095</pqid></control><display><type>article</type><title>Recombinant Vaccinia/Fowlpox NY-ESO-1 Vaccines Induce Both Humoral and Cellular NY-ESO-1-Specific Immune Responses in Cancer Patients</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>PubMed Central</source><creator>Jäger, Elke ; Karbach, Julia ; Gnjatic, Sacha ; Neumann, Antje ; Bender, Armin ; Valmori, Danila ; Ayyoub, Maha ; Ritter, Erika ; Ritter, Gerd ; Jäger, Dirk ; Panicali, Dennis ; Hoffman, Eric ; Pan, Linda ; Oettgen, Herbert ; Old, Lloyd J. ; Knuth, Alexander</creator><creatorcontrib>Jäger, Elke ; Karbach, Julia ; Gnjatic, Sacha ; Neumann, Antje ; Bender, Armin ; Valmori, Danila ; Ayyoub, Maha ; Ritter, Erika ; Ritter, Gerd ; Jäger, Dirk ; Panicali, Dennis ; Hoffman, Eric ; Pan, Linda ; Oettgen, Herbert ; Old, Lloyd J. ; Knuth, Alexander</creatorcontrib><description>NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination.</description><identifier>ISSN: 0027-8424</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.0606512103</identifier><identifier>PMID: 16984998</identifier><language>eng</language><publisher>United States: National Academy of Sciences</publisher><subject>Antibodies ; Antibodies - blood ; Antibody Formation - immunology ; Antigens ; Biological Sciences ; Cancer ; Cancer Vaccines - adverse effects ; Cancer Vaccines - genetics ; Cancer Vaccines - immunology ; CD8-Positive T-Lymphocytes - immunology ; Cells ; Clone Cells ; Cohort Studies ; Cytotoxicity, Immunologic - immunology ; Epitopes ; Epitopes - immunology ; Fowlpox virus - metabolism ; Humans ; Immune response ; Immune system ; Immunity, Cellular - immunology ; Melanoma ; Membrane Proteins - immunology ; Neoplasm Proteins - immunology ; Neoplasms - immunology ; Peptide Fragments - immunology ; Reactivity ; T lymphocytes ; Tumors ; Vaccination ; Vaccines ; Vaccines, Synthetic - adverse effects ; Vaccines, Synthetic - genetics ; Vaccines, Synthetic - immunology ; Vaccinia virus - genetics</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 2006-09, Vol.103 (39), p.14453-14458</ispartof><rights>Copyright 2006 National Academy of Sciences of the United States of America</rights><rights>Copyright National Academy of Sciences Sep 26, 2006</rights><rights>2006 by The National Academy of Sciences of the USA 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5113-9f739873e2daccc2f8ee9361d3d73940d177c95f07263de15f4b4bf0087168f43</citedby><cites>FETCH-LOGICAL-c5113-9f739873e2daccc2f8ee9361d3d73940d177c95f07263de15f4b4bf0087168f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.pnas.org/content/103/39.cover.gif</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30050395$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30050395$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16984998$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jäger, Elke</creatorcontrib><creatorcontrib>Karbach, Julia</creatorcontrib><creatorcontrib>Gnjatic, Sacha</creatorcontrib><creatorcontrib>Neumann, Antje</creatorcontrib><creatorcontrib>Bender, Armin</creatorcontrib><creatorcontrib>Valmori, Danila</creatorcontrib><creatorcontrib>Ayyoub, Maha</creatorcontrib><creatorcontrib>Ritter, Erika</creatorcontrib><creatorcontrib>Ritter, Gerd</creatorcontrib><creatorcontrib>Jäger, Dirk</creatorcontrib><creatorcontrib>Panicali, Dennis</creatorcontrib><creatorcontrib>Hoffman, Eric</creatorcontrib><creatorcontrib>Pan, Linda</creatorcontrib><creatorcontrib>Oettgen, Herbert</creatorcontrib><creatorcontrib>Old, Lloyd J.</creatorcontrib><creatorcontrib>Knuth, Alexander</creatorcontrib><title>Recombinant Vaccinia/Fowlpox NY-ESO-1 Vaccines Induce Both Humoral and Cellular NY-ESO-1-Specific Immune Responses in Cancer Patients</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination.</description><subject>Antibodies</subject><subject>Antibodies - blood</subject><subject>Antibody Formation - immunology</subject><subject>Antigens</subject><subject>Biological Sciences</subject><subject>Cancer</subject><subject>Cancer Vaccines - adverse effects</subject><subject>Cancer Vaccines - genetics</subject><subject>Cancer Vaccines - immunology</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cells</subject><subject>Clone Cells</subject><subject>Cohort Studies</subject><subject>Cytotoxicity, Immunologic - immunology</subject><subject>Epitopes</subject><subject>Epitopes - immunology</subject><subject>Fowlpox virus - metabolism</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunity, Cellular - immunology</subject><subject>Melanoma</subject><subject>Membrane Proteins - immunology</subject><subject>Neoplasm Proteins - immunology</subject><subject>Neoplasms - immunology</subject><subject>Peptide Fragments - immunology</subject><subject>Reactivity</subject><subject>T lymphocytes</subject><subject>Tumors</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Synthetic - adverse effects</subject><subject>Vaccines, Synthetic - genetics</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Vaccinia virus - genetics</subject><issn>0027-8424</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqFkk9v1DAQxS0EotuFMyeQxQGJQ7ozsfPHFyRYtXSliqIWkDhZXsehXiV2iJNSPgDfGy8b7QKXnnyY3zy_NzOEPEM4QSjYonMqnEAOeYYpAntAZggCk5wLeEhmAGmRlDzlR-Q4hA0AiKyEx-QIc1FyIcoZ-XVltG_X1ik30C9Ka-usWpz5H03n7-iHr8np9WWCU8UEunLVqA1954cbej62vlcNVa6iS9M0Y6P6fUty3Rlta6vpqm1HZ-iVCZ13IWpYR5fKadPTj2qwxg3hCXlUqyaYp9M7J5_PTj8tz5OLy_er5duLRGeILBF1wURZMJNW0Y9O69IYwXKsWBULHCosCi2yGoo0Z5XBrOZrvq4BygLzsuZsTt7sdLtx3ZpKx79jANn1tlX9T-mVlf9WnL2R3_ytxKwALNMo8GoS6P330YRBtjbomF0548cg81IA8riJ-0CMvqGIoebk5X_gxo-9i1OQKSD7s7MILXaQ7n0Ivan3lhHk9hDk9hDk4RBix4u_kx74afMReD0B286DHJNMSOQ8Y7Iem2Ywd0Nk6T1sRJ7vkE0YfL9nov8MWEzwGzcY0EU</recordid><startdate>20060926</startdate><enddate>20060926</enddate><creator>Jäger, Elke</creator><creator>Karbach, Julia</creator><creator>Gnjatic, Sacha</creator><creator>Neumann, Antje</creator><creator>Bender, Armin</creator><creator>Valmori, Danila</creator><creator>Ayyoub, Maha</creator><creator>Ritter, Erika</creator><creator>Ritter, Gerd</creator><creator>Jäger, Dirk</creator><creator>Panicali, Dennis</creator><creator>Hoffman, Eric</creator><creator>Pan, Linda</creator><creator>Oettgen, Herbert</creator><creator>Old, Lloyd J.</creator><creator>Knuth, Alexander</creator><general>National Academy of Sciences</general><general>National Acad Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7QO</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20060926</creationdate><title>Recombinant Vaccinia/Fowlpox NY-ESO-1 Vaccines Induce Both Humoral and Cellular NY-ESO-1-Specific Immune Responses in Cancer Patients</title><author>Jäger, Elke ; Karbach, Julia ; Gnjatic, Sacha ; Neumann, Antje ; Bender, Armin ; Valmori, Danila ; Ayyoub, Maha ; Ritter, Erika ; Ritter, Gerd ; Jäger, Dirk ; Panicali, Dennis ; Hoffman, Eric ; Pan, Linda ; Oettgen, Herbert ; Old, Lloyd J. ; Knuth, Alexander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5113-9f739873e2daccc2f8ee9361d3d73940d177c95f07263de15f4b4bf0087168f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antibodies</topic><topic>Antibodies - blood</topic><topic>Antibody Formation - immunology</topic><topic>Antigens</topic><topic>Biological Sciences</topic><topic>Cancer</topic><topic>Cancer Vaccines - adverse effects</topic><topic>Cancer Vaccines - genetics</topic><topic>Cancer Vaccines - immunology</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cells</topic><topic>Clone Cells</topic><topic>Cohort Studies</topic><topic>Cytotoxicity, Immunologic - immunology</topic><topic>Epitopes</topic><topic>Epitopes - immunology</topic><topic>Fowlpox virus - metabolism</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunity, Cellular - immunology</topic><topic>Melanoma</topic><topic>Membrane Proteins - immunology</topic><topic>Neoplasm Proteins - immunology</topic><topic>Neoplasms - immunology</topic><topic>Peptide Fragments - immunology</topic><topic>Reactivity</topic><topic>T lymphocytes</topic><topic>Tumors</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Synthetic - adverse effects</topic><topic>Vaccines, Synthetic - genetics</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Vaccinia virus - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jäger, Elke</creatorcontrib><creatorcontrib>Karbach, Julia</creatorcontrib><creatorcontrib>Gnjatic, Sacha</creatorcontrib><creatorcontrib>Neumann, Antje</creatorcontrib><creatorcontrib>Bender, Armin</creatorcontrib><creatorcontrib>Valmori, Danila</creatorcontrib><creatorcontrib>Ayyoub, Maha</creatorcontrib><creatorcontrib>Ritter, Erika</creatorcontrib><creatorcontrib>Ritter, Gerd</creatorcontrib><creatorcontrib>Jäger, Dirk</creatorcontrib><creatorcontrib>Panicali, Dennis</creatorcontrib><creatorcontrib>Hoffman, Eric</creatorcontrib><creatorcontrib>Pan, Linda</creatorcontrib><creatorcontrib>Oettgen, Herbert</creatorcontrib><creatorcontrib>Old, Lloyd J.</creatorcontrib><creatorcontrib>Knuth, Alexander</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jäger, Elke</au><au>Karbach, Julia</au><au>Gnjatic, Sacha</au><au>Neumann, Antje</au><au>Bender, Armin</au><au>Valmori, Danila</au><au>Ayyoub, Maha</au><au>Ritter, Erika</au><au>Ritter, Gerd</au><au>Jäger, Dirk</au><au>Panicali, Dennis</au><au>Hoffman, Eric</au><au>Pan, Linda</au><au>Oettgen, Herbert</au><au>Old, Lloyd J.</au><au>Knuth, Alexander</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant Vaccinia/Fowlpox NY-ESO-1 Vaccines Induce Both Humoral and Cellular NY-ESO-1-Specific Immune Responses in Cancer Patients</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>2006-09-26</date><risdate>2006</risdate><volume>103</volume><issue>39</issue><spage>14453</spage><epage>14458</epage><pages>14453-14458</pages><issn>0027-8424</issn><eissn>1091-6490</eissn><abstract>NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination.</abstract><cop>United States</cop><pub>National Academy of Sciences</pub><pmid>16984998</pmid><doi>10.1073/pnas.0606512103</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-8424 |
| ispartof | Proceedings of the National Academy of Sciences - PNAS, 2006-09, Vol.103 (39), p.14453-14458 |
| issn | 0027-8424 1091-6490 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19360711 |
| source | JSTOR Archival Journals and Primary Sources Collection; PubMed Central |
| subjects | Antibodies Antibodies - blood Antibody Formation - immunology Antigens Biological Sciences Cancer Cancer Vaccines - adverse effects Cancer Vaccines - genetics Cancer Vaccines - immunology CD8-Positive T-Lymphocytes - immunology Cells Clone Cells Cohort Studies Cytotoxicity, Immunologic - immunology Epitopes Epitopes - immunology Fowlpox virus - metabolism Humans Immune response Immune system Immunity, Cellular - immunology Melanoma Membrane Proteins - immunology Neoplasm Proteins - immunology Neoplasms - immunology Peptide Fragments - immunology Reactivity T lymphocytes Tumors Vaccination Vaccines Vaccines, Synthetic - adverse effects Vaccines, Synthetic - genetics Vaccines, Synthetic - immunology Vaccinia virus - genetics |
| title | Recombinant Vaccinia/Fowlpox NY-ESO-1 Vaccines Induce Both Humoral and Cellular NY-ESO-1-Specific Immune Responses in Cancer Patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T06%3A49%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20Vaccinia/Fowlpox%20NY-ESO-1%20Vaccines%20Induce%20Both%20Humoral%20and%20Cellular%20NY-ESO-1-Specific%20Immune%20Responses%20in%20Cancer%20Patients&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=J%C3%A4ger,%20Elke&rft.date=2006-09-26&rft.volume=103&rft.issue=39&rft.spage=14453&rft.epage=14458&rft.pages=14453-14458&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.0606512103&rft_dat=%3Cjstor_proqu%3E30050395%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5113-9f739873e2daccc2f8ee9361d3d73940d177c95f07263de15f4b4bf0087168f43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=201300095&rft_id=info:pmid/16984998&rft_jstor_id=30050395&rfr_iscdi=true |